Valiant Laboratories Ltd
VALIANTLAB NSE
Valiant Laboratories Ltd
HealthcareNSE: VALIANTLAB BSE: 543998 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹567 Cr
Volatility
High Risk
P/E Ratio
35.9
EBITDA
₹6.39 Cr
Return on Equity
-0.94%
Debt to Equity
0.15
Book Value
₹57.24
52W High
₹100.52
52W Low
₹49.51
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Valiant Laboratories Ltd insights
29 extracted metrics + investor summaries across FY23–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
2- Company has reduced debt.
- Company is expected to give good quarter
Weaknesses
1- Company has a low return on equity of -1.41% over last 3 years.
Growth Rate
Revenue Growth
71.09% ↗
Net Income Growth
-60.45% ↘
Cash Flow Change
-30.69% ↘
ROE
-823.08% ↘
ROCE
77.27% ↘
EBITDA Margin (Avg.)
392.59% ↘
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 60 | 41 | 31 | 19 | 21 | 35 | 58 | 47 | 46 | 52 | 92 | 115 |
| Expenses | 48 | 61 | 47 | 35 | 21 | 28 | 35 | 54 | 44 | 46 | 53 | 87 | 86 |
| Operating Profit | 4 | -1 | -6 | -5 | -2 | -7 | 1 | 4 | 2 | 0 | -1 | 5 | 29 |
| OPM % | 7% | -2.3% | -16% | -15% | -13% | -31% | 1.8% | 7% | 5% | 0.2% | -1.7% | 5% | 25% |
| Other Income | 2 | 3 | 2 | 2 | 3 | 3 | 2 | -2 | 1 | 1 | 1 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 |
| PBT | 6 | 1 | -5 | -3 | 0 | -4 | 2 | 1 | 2 | 0 | -3 | 1 | 26 |
| Tax % | 26% | 25% | -31% | -52% | 219% | 21% | -44% | 26% | 26% | 25% | 136% | -68% | 19% |
| Net Profit | 4 | 1 | -4 | -1 | -1 | -5 | 2 | 1 | 2 | 0 | -7 | 2 | 21 |
| EPS in Rs | 1.05 | 0.19 | -0.64 | -0.23 | -0.09 | -0.87 | 0.43 | 0.13 | 0.34 | 0.04 | -1.3 | 0.32 | 3.88 |
Profit & Loss
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| Sales | 334 | 182 | 133 | 237 | 306 |
| Expenses | 299 | 190 | 138 | 231 | 273 |
| Operating Profit | 35 | -8 | -5 | 6 | 33 |
| OPM % | 11% | -4.6% | -3.5% | 2.7% | 11% |
| Other Income | 5 | 10 | 5 | 2 | 3 |
| Interest | 0 | 0 | 0 | 2 | 3 |
| Depreciation | 2 | 2 | 2 | 6 | 8 |
| PBT | 38 | -1 | -2 | 1 | 25 |
| Tax % | 24% | -142% | 46% | 525% | — |
| Net Profit | 29 | 0 | -2 | -3 | 16 |
| EPS in Rs | 7.13 | 0.06 | -0.41 | -0.6 | 2.94 |
| Div. Payout % | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 33 | 43 | 43 | 54 |
| Reserves | 68 | 193 | 191 | 257 |
| Borrowings | 60 | 77 | 122 | 46 |
| Other Liabilities | 52 | 29 | 45 | 107 |
| Total Liabilities | 213 | 343 | 401 | 464 |
| Fixed Assets | 48 | 50 | 48 | 227 |
| CWIP | 1 | 43 | 156 | 6 |
| Investments | 34 | 38 | 0 | 28 |
| Other Assets | 130 | 212 | 197 | 202 |
| Total Assets | 213 | 343 | 401 | 464 |
Cash Flow
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Operating | 56 | 2 | 1 | -10 |
| Investing | -55 | -144 | -53 | 7 |
| Financing | -1 | 152 | 45 | 2 |
| Net Cash Flow | 0 | 10 | -7 | -1 |
| Free Cash Flow | 18 | -44 | -112 | -45 |
| CFO/OP | 185 | -11 | 25 | -147 |
Ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 97 | 92 | 197 | 144 |
| Inventory Days | 17 | 22 | 13 | 84 |
| Days Payable | 62 | 56 | 128 | 174 |
| Cash Conversion Cycle | 52 | 57 | 82 | 54 |
| Working Capital Days | 70 | 106 | 156 | 156 |
| ROCE % | — | -2% | -1% | 1% |
Documents
2
Audited Standalone And Consolidated Financial Results For Quarter And Year Ended March 31 2026. 14 May 2026
3
Audited Standalone And Consolidated Financial Results For Quarter And Year Ended March 31 2026. 14 May 2026
1
Board Meeting Intimation for Approval Of Financial Results For Quarter And Year Ended March 31, 2026
11h - Board meeting on May 14, 2026 to approve audited Q4 and FY26 standalone and consolidated results. 11h - Board meeting on May 14, 2026 to approve audited Q4 and FY26 standalone and consolidated results.
2
Announcement under Regulation 30 (LODR)-Change in Management
23 Apr - Q.C Manager Bhanudas D. Patil resigned effective April 22, 2026. 23 Apr - Q.C Manager Bhanudas D. Patil resigned effective April 22, 2026.
3
Announcement under Regulation 30 (LODR)-Change in Management
12h - Q.C Manager Bhanudas D. Patil resigned effective April 22, 2026. 12h - Q.C Manager Bhanudas D. Patil resigned effective April 22, 2026.
4
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Apr - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026; all securities held in demat form. 13 Apr - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026; all securities held in demat form.
Frequently Asked Questions about Valiant Laboratories Ltd
What does Valiant Laboratories Ltd do?
Incorporated in 1980, Valiant Laboratories
Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]
Where is Valiant Laboratories Ltd (VALIANTLAB) listed?
Valiant Laboratories Ltd is listed on the Indian stock exchanges. It is listed on NSE: VALIANTLAB and BSE: 543998. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Valiant Laboratories Ltd belong to?
Valiant Laboratories Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Valiant Laboratories Ltd?
Valiant Laboratories Ltd has a market capitalisation of approximately ₹567.46 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Valiant Laboratories Ltd?
The Price-to-Earnings (PE) ratio of Valiant Laboratories Ltd is 35.90. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Valiant Laboratories Ltd?
Over the past 52 weeks, Valiant Laboratories Ltd has traded between a low of ₹49.51 and a high of ₹100.52. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Valiant Laboratories Ltd?
Valiant Laboratories Ltd has a Return on Equity (ROE) of -0.94%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Valiant Laboratories Ltd on Tapetide?
On Tapetide, you can view Valiant Laboratories Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1980, Valiant Laboratories Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]